Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
- Kanjinti
Descriptions
Trastuzumab-anns injection is used together with other cancer medicines (eg, doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or docetaxel and carboplatin) or used alone after a previous treatment with an anthracycline medicine to treat HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer.
Trastuzumab-anns injection is also used to treat HER2-overexpressing metastatic (cancer that has spread) breast cancer in patients who have received one or more cancer treatments. It is also used together with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer.
Trastuzumab-anns injection is also used together with cisplatin and capecitabine or 5-fluorouracil to treat HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma (stomach or esophagus cancer) in patients who have not received treatment previously.
Trastuzumab-anns prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).
Trastuzumab-anns is a monoclonal antibody. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by trastuzumab-anns, other effects will also occur. Some of these may be serious and must be reported to your doctor.
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.